On Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q4 2023 earnings per share (EPS) of -$0.21, up 5% year over year. Total Cardiff Oncology earnings for the quarter were -$9.34 million. In the same quarter last year, Cardiff Oncology's earnings per share (EPS) was -$0.20.
As of Q1 2024, Cardiff Oncology's earnings has grown year over year. Cardiff Oncology's earnings in the past year totalled -$41.47 million.
What is CRDF's earnings date?
Cardiff Oncology's earnings date is Invalid Date. Add CRDF to your watchlist to be reminded of CRDF's next earnings announcement.
What was CRDF's revenue last quarter?
On Invalid Date, Cardiff Oncology (NASDAQ: CRDF) reported Q4 2023 revenue of $156.00 thousand up 21.88% year over year. In the same quarter last year, Cardiff Oncology's revenue was $128.00 thousand.
What was CRDF's revenue growth in the past year?
As of Q1 2024, Cardiff Oncology's revenue has grown 26.42% year over year. This is 142.87 percentage points lower than the US Biotechnology industry revenue growth rate of 169.3%. Cardiff Oncology's revenue in the past year totalled $488.00 thousand.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.